Leadership Shift at FDA as OTC-Drug Office Director Moves to New Role

On December 2, 2025, the U.S. Food and Drug Administration (FDA) announced a leadership change within its ranks, with Theresa Michele, the longtime head of the Over-the-Counter (OTC) drugs office, transitioning to a new role in the agency’s Center for Medical Devices. This shift is effective immediately and comes amid growing internal reviews and criticism regarding the pace at which the FDA has been approving nonprescription medications.

Sources within the industry suggest that this move reflects increasing pressure on the FDA to expedite the approval process for OTC treatments and streamline regulatory oversight. The pace of OTC drug approvals has been a point of contention for some time, with calls for more efficiency and responsiveness to public health needs. Michele’s transition is expected to help address these concerns, as the FDA faces mounting expectations to accelerate access to critical OTC medications.

This leadership change follows the retirement of the FDA’s drug-evaluation chief, signaling a broader organizational restructuring within the agency. The changes come as part of a larger effort under the current leadership to modernize and improve regulatory practices, especially in areas like OTC drug approvals and medical device regulation. Michele’s new role in the Center for Medical Devices highlights the FDA’s intention to bring fresh perspectives and leadership to the regulatory processes surrounding medical technologies.

The impact of this leadership shift is being closely monitored by healthcare stakeholders and biotech firms, who are particularly interested in how the restructuring will affect approval timelines for new OTC drugs. There is also a keen interest in the potential for greater regulatory clarity in the medical device sector, which could benefit from streamlined processes under the new leadership. As the FDA moves forward with these changes, industry players are watching to see how the agency adapts to the evolving demands of public health and technological innovation.